key: cord-1020048-iaye5aww
authors: Spangler, Julie; Martley, Timothy James; Schieber, Timothy; Mohamed, Adham; Woods, Mark
title: Assessment of narcotic, sedative, and neuromuscular blocker needs of patients with COVID-19 requiring invasive mechanical ventilation
date: 2021-02-18
journal: Am J Health Syst Pharm
DOI: 10.1093/ajhp/zxab055
sha: bbcd3a6182612cfa0d8b932c3a38e374577b4fff
doc_id: 1020048
cord_uid: iaye5aww

In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

M a n u s c r i p t 3 As of November 15, 2020, over 11 million cases of Coronavirus disease 2019 have been reported in the United States. 1 In hospitalized patients with COVID-19, 20% of them will develop critical illness and require admission in intensive care. 2, 3 Among patients who developed critical illness, 39% to 79% required invasive mechanical ventilation. 2, 3 Patients requiring mechanical ventilation for COVID-19 appear to need uncommonly high amounts of sedatives, opioids, and neuromuscular blockers. Pharmacy departments across the nation are struggling to maintain an adequate inventory of drugs typically used in intubated patients amid COVID-19 surges. This letter aims to report the average narcotic, sedative, and neuromuscular blocking agent (NMBA) requirements for intubated patients with COVID-19.

A retrospective review of patients at Saint Luke's Health System with confirmed COVID-19 requiring mechanical ventilation was performed to determine average daily doses of narcotics, sedatives, and NMBAs. This review was conducted from March 1, 2020 to August 22, 2020, with approval from Saint Luke's Health System Institutional Review Board. Secondary outcomes were assessed for association between several baseline variables such as age, sex, weight, and baseline PO 2 /FiO 2 ratio and the patient's daily requirements of narcotics, sedatives, and NMBAs. Descriptive statistics were utilized to describe the baseline characteristics. Multiple regression was used to assess the effect of variables on daily requirements. (Table 1) . Younger age and male gender were associated with statistically significant higher opioid and sedative requirements (P < 0.05).

The daily narcotics doses, and propofol requirements, were significantly higher in patients who received NMBAs compared to no NMBAs (Table 2) . Furthermore, more patients received midazolam infusion in the NMBAs group (n = 19) compared with the no NMBAs group (n = 6) ( Table 2 ).

The average daily propofol dose in the ACURASYS trial was 1,939 mg and 1,422 mg in the NMBA and placebo groups, respectively, compared with 3,040 mg in this cohort (3,990 mg in NMBAs group and 1,804 mg in the non-NMBAs group), but the daily midazolam dose in the ACURASYS trial was 142 mg and 171 mg in the NMBA and placebo groups, respectively, compared with 79 mg in this cohort. 4 The propofol mean daily dose in the SPICE III trial was also lower compared with this cohort. 5 The median daily propofol dose in the usual care group was approximately 1,495 mg, compared with the median daily dose of 2,721 mg in this cohort. (The mean propofol dose was 1,804 mg in the non-NMBAs group.) In the SPICE III trial, the mean daily midazolam dose in the usual care group was significantly lower than the mean daily midazolam doses in this cohort and in the non-NMBAs group (26 mg vs 70.8 mg vs 105.7 mg). 5 This cohort required significantly higher opioid doses compared with the SPICE III cohort (965 MME vs 270 MME). 5 The non-NMBAs group also required higher opioid doses compared with the SPICE III cohort (692.8 MME vs 270 MME). 5 However, the sedation and opioid dosing requirements in this cohort were lower than in the MIDEX and PRODEX studies. 6 A c c e p t e d M a n u s c r i p t 5 To our knowledge, this review is the first analysis of the narcotics, sedatives, and NMBA requirements in mechanically ventilated patients with COVID-19. Severely ill patients with COVID-19 who are intubated may require substantially higher doses of narcotics, sedatives, and paralyzing agents to maintain adequate sedation and ventilation, based on our data. The results of this study suggest pharmacy departments may need to create new models to ensure they have adequate inventory during COVID-19 surges. The analysis also gives a brief glimpse into baseline characteristics that may affect dosing requirements in these unique patients.

A c c e p t e d M a n u s c r i p t 

Case-Surveillance/COVID-19-Case-Surveillance-Public-Use-Data/vbim-akqf

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The Lancet

Patient characteristics and outcomes of 11,721 patients with coronavirus disease 2019 (COVID-19) hospitalized across the United States

Neuromuscular blockers in early acute respiratory distress syndrome

Early sedation with dexmedetomidine in critically ill patients

Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials

A c c e p t e d M a n u s c r i p t